Home / Stocks / SHC

Sotera Health (SHC, Life Sciences Tools & Services) Stock Valuation & Fair Value Trading above fair value

Sotera Health (SHC, Life Sciences Tools & Services) trades at a blended P/E of 19.7, about 10% below its historical normal valuation, with a forward growth estimate of 9.7% and a PEG of 2.04. Analysts' one-year estimates have been hit 40% of the time. Priced at its historical normal P/E of 21.9 on the same blended earnings, the 2026-09-18 close of $18.73 corresponds to about $20.80 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
19.7
Normal P/E
21.9
PEG
2.04
Fwd growth
9.7%
Div yield
0.0%
RSI (14)
43.5
Neutral
Technical context
  • Price $18.29 at the 2026-09-23 close, 3.1% below the 20-day average ($18.87) and 1.2% below the 50-day ($18.51).
  • RSI (14) at 43.5.
  • 52-week range $13.13 to $19.57: the price is 6.5% below the high and 39.3% above the low.

The Street vs SeerForecast

Wall Street's mean price target for SHC is $22.72 across 9 analysts, 24.2% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: trading above fair value. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been trading above fair value since 2026-07-31.

Blended P/E and rating by weekBlended P/E moved from 19.3 to 19.7 between 2026-07-31 and 2026-09-21, against a normal P/E of 21.9, with 0 rating changes over 18 recorded weeks.2026-07-31: P/E 19.3, Trading above fair value (recalculated)2026-08-03: P/E 19.3, Trading above fair value2026-08-07: P/E 19.3, Trading above fair value (recalculated)2026-08-10: P/E 20.2, Trading above fair value2026-08-14: P/E 20.2, Trading above fair value (recalculated)2026-08-17: P/E 20.1, Trading above fair value2026-08-21: P/E 20.1, Trading above fair value (recalculated)2026-08-24: P/E 20.8, Trading above fair value2026-08-27: P/E 20.8, Trading above fair value (recalculated)2026-08-28: P/E 20.8, Trading above fair value (recalculated)2026-08-30: P/E 20.8, Trading above fair value (recalculated)2026-08-31: P/E 20.4, Trading above fair value2026-09-05: P/E 20.4, Trading above fair value (recalculated)2026-09-07: P/E 20.0, Trading above fair value2026-09-12: P/E 20.0, Trading above fair value (recalculated)2026-09-14: P/E 19.4, Trading above fair value2026-09-19: P/E 19.4, Trading above fair value (recalculated)2026-09-21: P/E 19.7, Trading above fair value20.021.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 21.9
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 19.3-12%Trading above fair value
2026-08-24P/E 20.8-5%Trading above fair value
2026-09-21P/E 19.7-10%Trading above fair value ← now

Frequently asked questions

Is Sotera Health stock overvalued?

At a blended P/E of 19.7 versus its historical normal P/E of 21.9, Sotera Health trades about 10% below its typical valuation, with a PEG of 2.04 on 9.7% forward growth. tickerseer currently rates it trading above fair value.

What is Sotera Health's fair value and PEG?

Sotera Health trades at a blended P/E of 19.7 against a historical normal P/E of 21.9, a PEG of 2.04, and a forward growth estimate of 9.7%. Priced at its historical normal P/E of 21.9 on the same blended earnings, the 2026-09-18 close of $18.73 corresponds to about $20.80 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Sotera Health changed?

tickerseer's rating has been trading above fair value since 2026-07-31.

What is the analyst price target for Sotera Health?

The mean Wall Street price target for Sotera Health is $22.72 across 9 analysts, 24.2% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Life Sciences Tools & Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track SHC free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.